# A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly

> **NCT01198132** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 129 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DIETARY_SUPPLEMENT:** Cholecalciferol (Vitamin D3)
- **DIETARY_SUPPLEMENT:** Placebo
- **DRUG:** Rebif

## Key facts

- **NCT ID:** NCT01198132
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-11
- **Target enrollment:** 129 (ACTUAL)
- **Last updated:** 2017-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01198132

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01198132, "A Multicentre Study of the Efficacy and Safety of Supplementary Treatment With Cholecalciferol in Patients With Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta-1a 44 µg 3 Times Weekly". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01198132. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*